Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SOUTH SAN FRANCISCO, Calif., March 27, 2017 -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the closing of its previously announced public offering of 7,854,500 shares of common stock, including 1,024,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds from the offering at a public offering price of $10.25 per share, before underwriting discounts and commissions and offering expenses, were approximately $80.5 million.
Leerink Partners acted as sole book-running manager for the offering. Wells Fargo Securities acted as lead manager and JMP Securities acted as co-manager for the offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was declared effective on November 24, 2015. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the prospectus related to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at [email protected], or by telephone at (800) 808-7525, ext. 6132.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera is headquartered in South San Francisco, California.
Investor Relations Contact: Jennifer McNealey [email protected] 650-870-1071
